This trial is active, not recruiting.

Condition breast cancer
Treatment capecitabine
Phase phase 2
Sponsor Pharmatech Oncology
Start date November 2001
Trial identifier NCT00026442, CDR0000069030, PHARMATECH-20010330, PHARMATECH-XEL-154, ROCHE-PHARMATECH-XEL-154


RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Randomized phase II trial to compare the effectiveness of two different doses of capecitabine in treating women who have advanced or metastatic breast cancer.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Primary purpose treatment

Eligibility Criteria

Female participants at least 18 years old.

DISEASE CHARACTERISTICS: - Histologically and/or cytologically confirmed breast cancer - Advanced and/or metastatic disease - At least 1 measurable lesion - At least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan - No CNS metastases - Hormone receptor status: - Not specified PATIENT CHARACTERISTICS: Age: - 18 and over Sex: - Female Menopausal status: - Not specified Performance status: - Karnofsky 70-100% Life expectancy: - At least 12 weeks Hematopoietic: - Neutrophil count at least 1,500/mm^3 - Platelet count at least 100,000/mm^3 Hepatic: - Bilirubin no greater than 1.25 times upper limit of normal (ULN) - AST/ALT no greater than 2.5 times ULN (5 times ULN if liver metastases present) - Alkaline phosphatase no greater than 2.5 times ULN (5 times ULN if liver metastases present OR 10 times ULN if bone metastases present) - No hepatitis Renal: - Creatinine no greater than 1.5 times ULN - Creatinine clearance at least 50 mL/min Cardiovascular: - No clinically significant cardiac disease - No congestive heart failure - No symptomatic coronary artery disease - No cardiac arrhythmias poorly controlled with medication - No myocardial infarction within the past 12 months even if adequately controlled with medication Other: - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - HIV negative - No severe pain inadequately controlled by analgesics - No prior severe and unexpected reaction to fluoropyrimidine therapy - No known hypersensitivity to fluorouracil - No impaired physical integrity of the upper gastrointestinal tract - No malabsorption syndrome - No inability to swallow tablets - No history of uncontrolled seizures, central nervous system disorder, or psychiatric disability that would preclude study participation - No serious uncontrolled infection PRIOR CONCURRENT THERAPY: Biologic therapy: - Not specified Chemotherapy: - At least 2 but no more than 3 prior chemotherapy regimens - At least 1 prior chemotherapy regimen containing paclitaxel and an anthracycline as adjuvant therapy or for advanced and/or metastatic disease Endocrine therapy: - Not specified Radiotherapy: - No prior radiotherapy to target lesions unless there is evidence of new disease within the irradiated field - No concurrent radiotherapy Surgery: - No prior organ allografts Other: - At least 4 weeks since prior investigational drug - No concurrent enrollment on other investigational study - No other concurrent anticancer agents

Additional Information

Official title A Pilot Trial Of Two Different Doses Of Capecitabine (XELODA) In Patients With Advanced And/Or Metastatic Breast Cancer
Description OBJECTIVES: - Compare the objective response rate in women with advanced or metastatic breast cancer treated with two dose levels of capecitabine. - Compare the duration of response, time to progression, time to treatment failure, survival, incidence of adverse events, and time to onset of the adverse experience in patients treated with this drug. - Compare the quality of life of patients treated with this drug. OUTLINE: This is a randomized, multicenter study. Patients are stratified according to Karnofsky performance status (70-80% vs 90-100%) and presence of hepatic metastases (yes vs no). Patients are randomized to one of two treatment arms. - Arm I: Patients receive lower-dose oral capecitabine twice daily on days 1-14. - Arm II: Patients receive higher-dose oral capecitabine twice daily on days 1-14. In both arms, courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline, at the end of the third and sixth courses, and at completion of therapy. PROJECTED ACCRUAL: A total of 120 patients (60 per treatment arm) will be accrued for this study within 9 months.
Trial information was received from ClinicalTrials.gov and was last updated in December 2013.
Information provided to ClinicalTrials.gov by National Cancer Institute (NCI).